Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus)

For the why behind the fact

Use this page to connect what you are memorizing.

Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.

Overview


Plain-Language Overview

Chikungunya spreads mainly through the bite of an infected mosquito. A typical illness starts suddenly with fever and severe pain in several joints, often on both sides of the body. Some people also develop a rash. Fever usually improves within a week, but joint pain can recur or persist for months and sometimes years. Dengue can look similar early in the illness, which affects the choice of pain medicine.

Clinical Definition

Chikungunya virus is an enveloped, positive-sense single-stranded RNA alphavirus in the Togaviridae family. Aedes aegypti and Aedes albopictus transmit it. Abrupt fever with severe bilateral polyarthralgia, often in the hands and feet, is the hallmark. Joint swelling and a maculopapular rash can accompany it. Acute illness generally improves within 7-10 days. Persistent synovitis or recurrent pain can resemble rheumatoid arthritis. Dengue and Zika share vectors and can circulate together.

Inciting Event

  • Bite from an infected Aedes mosquito transmitting Chikungunya virus.

  • Introduction of virus into the bloodstream initiating systemic infection.

Latency Period

  • Incubation is usually 3-7 days after an infectious bite, with a reported range of 1-12 days.

  • Among symptomatic patients, fever and joint pain usually begin abruptly after incubation. Some infections remain asymptomatic.

Diagnostic Delay

  • Symptom overlap with dengue and Zika virus infections often leads to initial misdiagnosis.

  • Lack of specific early diagnostic tests in resource-limited settings delays confirmation.

  • Mild or atypical presentations may be mistaken for other viral illnesses or autoimmune arthritis.

  • Low clinical suspicion in non-endemic areas contributes to delayed diagnosis.

Clinical Presentation


Signs & Symptoms

  • High fever with abrupt onset lasting 2-5 days

  • Severe polyarthralgia or polyarthritis causing joint stiffness and swelling

  • A maculopapular rash may develop after fever begins. The timing and distribution vary.

  • Headache and myalgia can accompany fever. Conjunctivitis can occur and also overlaps with Zika.

  • Fatigue and malaise persisting beyond acute illness

History of Present Illness

  • Ask about abrupt high fever and severe bilateral joint pain, often affecting the hands, feet, wrists or ankles. Some patients also develop frank joint swelling.

  • Ask when a rash appeared relative to the fever and whether it involved the trunk or limbs. The exposure history and joint symptoms help interpret this nonspecific eruption.

  • Headache, myalgia, nausea or conjunctivitis may accompany the fever.

  • Joint pain may persist for weeks to months, sometimes evolving into chronic arthritis.

  • Symptoms typically resolve within 7 to 10 days, but fatigue and joint stiffness may linger.

Past Medical History

  • Ask about prior arboviral illness, recent travel and current local outbreaks. Several arboviruses can circulate at the same destination.

  • History of chronic inflammatory arthritis can complicate diagnosis and management.

  • Immunosuppressive conditions or therapies may alter disease severity.

Family History

  • No known heritable predisposition to Chikungunya virus infection or disease severity.

  • Family clustering may occur due to shared environmental exposure to infected mosquitoes.

Physical Exam Findings

  • Symmetric polyarthritis predominantly affecting small joints of the hands, wrists, and ankles

  • Maculopapular rash often involving the trunk and extremities

  • Tenderness and swelling of affected joints without joint deformity

  • Lymphadenopathy may be present in some cases

  • Conjunctival injection without purulent discharge

Diagnostic Workup


Diagnostic Criteria

Consider chikungunya when fever and new polyarthralgia follow exposure in an area with transmission. During the first 8 days of illness, serum RT-PCR can detect viral RNA. Toward the end of the first week, test for chikungunya-specific IgM and confirm positive results by neutralizing antibody testing because false positives occur. If an early specimen is negative and suspicion persists, obtain convalescent serum. Evaluate for dengue and other locally circulating causes.

Pathophysiology


Key Mechanisms

  • Infection of fibroblasts and macrophages by Chikungunya virus leads to robust innate immune activation and cytokine release causing systemic inflammation.

  • Inflammation in and around joints can cause symmetric pain, synovitis and stiffness. The relative roles of viral tissue infection and host immunity vary across disease stages.

  • Systemic infection may cause a maculopapular rash. Clinically significant plasma leakage or shock raises concern for severe dengue.

  • Adaptive immune response with CD8+ T cell activation and neutralizing antibodies helps clear infection but may contribute to tissue damage.

  • Researchers have identified viral material in synovial tissue in selected cases. A separate chronic arthritis cohort had no detectable virus in synovial fluid. Persistent symptoms alone cannot establish ongoing viral replication.

InvolvementDetails
Organs

Joints are affected by viral-induced inflammation leading to polyarthritis and pain.

Skin manifests the characteristic rash associated with chikungunya fever.

Tissues

Synovial tissue is the primary site of inflammation causing polyarthritis and joint swelling.

Skin is involved due to the characteristic maculopapular rash caused by viral infection.

Cells

Macrophages are infected by the chikungunya virus and contribute to the inflammatory response in joints.

T lymphocytes mediate immune response and contribute to chronic joint inflammation in some cases.

Chemical Mediators

Studies have associated IL-6 with inflammation in some people with persistent joint pain. Diagnosis relies on virologic testing and the clinical course.

Researchers have observed differences in TNF-alpha levels between groups with persistent symptoms and recovered patients. The association does not establish TNF as the cause of joint damage in an individual.

Interferon-alpha (IFN-α) is part of the antiviral immune response against the chikungunya virus.

Treatments


Pharmacological Treatments

  • Acetaminophen

    • Mechanism:
      • Inhibits central prostaglandin synthesis to reduce fever and pain.

    • Side effects:
      • Hepatotoxicity with overdose

      • Rare allergic reactions

    • Clinical role:
      • Acetaminophen is preferred for acute fever and pain while dengue is being evaluated. Provide hydration and assess for dengue warning signs.

  • NSAIDs

    • Mechanism:
      • Inhibit cyclooxygenase enzymes to reduce inflammation, pain, and fever.

    • Side effects:
      • Gastrointestinal bleeding

      • Renal impairment

      • Increased cardiovascular risk

    • Clinical role:
      • Consider an NSAID for joint inflammation after dengue has been ruled out and individual bleeding, renal and cardiovascular risks have been assessed.

Non-pharmacological Treatments

  • Maintain adequate hydration to prevent dehydration from fever and systemic illness.

  • Rest to reduce joint stress and promote recovery during acute polyarthritis.

  • Local cooling may ease joint discomfort. Persistent pain or reduced mobility may benefit from physical therapy and clinical reassessment.

Prevention


Pharmacological Prevention

  • VIMKUNYA is a recombinant virus-like particle vaccine licensed in the United States for people 12 years and older. There is no specific antiviral prophylaxis.

  • In the United States, vaccination is recommended for eligible travelers to an area with a chikungunya outbreak and for laboratory personnel at risk of exposure to the virus. It may be considered for an extended stay in an area with elevated risk.

  • Vaccination is generally deferred during pregnancy. If exposure risk is high and unavoidable, discuss benefits and risks with the treating clinician.

Non-pharmacological Prevention

  • Mosquito control measures including elimination of standing water to reduce Aedes mosquito breeding

  • Use of insect repellents containing DEET or picaridin to prevent mosquito bites

  • Protective clothing to minimize skin exposure in endemic areas

  • Window screens and bed nets to reduce indoor mosquito contact

  • Aedes mosquitoes commonly bite during the day. During the first week of illness, prevent further mosquito bites so mosquitoes cannot carry the virus to other people.

Outcome & Complications


Complications

  • Chronic inflammatory arthritis mimicking rheumatoid arthritis

  • Neurological complications including meningoencephalitis and Guillain-Barré syndrome

  • Myocarditis and cardiac arrhythmias in severe cases

  • Hemorrhagic manifestations are rare but possible

  • Patients infected around birth may develop severe neonatal disease. Rare complications in severe cases also include hepatitis, nephritis and bullous skin lesions.

Short-term Sequelae Long-term Sequelae
  • Persistent joint pain and swelling lasting weeks to months after acute infection

  • Fatigue and weakness during convalescence

  • Post-viral rash pigmentation changes

  • Transient lymphadenopathy

  • Lymphopenia or thrombocytopenia can occur during acute illness. Marked or worsening cytopenias warrant assessment for dengue and other causes.

  • Chronic polyarthritis resembling seronegative rheumatoid arthritis lasting months to years

  • Joint deformities and functional impairment in severe chronic cases

  • Persistent fatigue and depression impacting quality of life

  • Rare neurological sequelae such as cognitive dysfunction

  • Persistent or relapsing synovitis can limit daily activity. Assess for post-chikungunya inflammatory arthritis and coexisting rheumatic disease when joint symptoms continue.

Differential Diagnoses


Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus) versus Dengue Fever

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus)

Dengue Fever

Local transmission or travel with exposure to Aedes aegypti or Aedes albopictus.

The same Aedes species can transmit dengue in overlapping areas. Mosquito species alone cannot separate these infections.

Abrupt fever and prominent bilateral joint pain, sometimes with rash or arthritis.

Fever, headache, retro-orbital pain or myalgia. Watch for warning signs, plasma leakage and bleeding, especially near defervescence.

Lymphopenia is a clue. Platelet counts can fall, so interpret the complete blood count with the clinical course.

Falling platelets and a rising hematocrit can suggest plasma leakage. These findings depend on timing and severity.

Early serum RT-PCR, or later chikungunya IgM confirmed with neutralizing antibodies.

A positive dengue NAAT or NS1 antigen confirms acute infection. A single positive dengue IgM is presumptive and may cross-react with other flaviviruses.

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus) versus Rheumatoid Arthritis

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus)

Rheumatoid Arthritis

Acute onset polyarthritis with fever and rash

Chronic symmetric polyarthritis with gradual onset over weeks to months

CHIKV testing and the exposure timeline support diagnosis. RF and anti-CCP results alone cannot establish or exclude post-infectious arthritis.

RF or anti-CCP can support RA in a patient with compatible synovitis. Seronegative RA also occurs.

Early radiographs can be normal. Persistent inflammatory symptoms warrant evaluation.

Early radiographs can also be normal. Erosions and joint-space loss may develop with progressive disease.

Acute fever usually resolves with supportive care. Joint symptoms may persist and require follow-up. Use NSAIDs only after evaluating for dengue.

Disease-modifying drugs can slow RA progression. Treatment response alone does not identify the cause of synovitis.

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus) versus Parvovirus B19 Infection

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus)

Parvovirus B19 Infection

Exposure to mosquito bites in endemic areas

Exposure to children with erythema infectiosum (fifth disease)

Fever with maculopapular rash and severe polyarthritis

Children commonly have a slapped-cheek or lacy rash. In adults, symmetric joint pain can predominate even without a rash.

Early RT-PCR or positive IgM confirmed with neutralizing antibodies.

Positive parvovirus B19 IgM serology

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus) versus Zika Virus Infection

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus)

Zika Virus Infection

Travel to areas with chikungunya virus transmission

Travel to areas with Zika virus transmission, often overlapping with dengue

High fever with prominent polyarthritis and rash

Mild fever, conjunctivitis, and maculopapular rash with mild arthralgia

Early serum RT-PCR or later IgM confirmed by neutralization.

Select Zika NAAT and serology according to timing and exposure. Isolated IgM can cross-react with dengue and needs careful interpretation.

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus) versus Systemic Lupus Erythematosus (SLE)

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus)

Systemic Lupus Erythematosus (SLE)

Abrupt fever and polyarthralgia after exposure. The fever usually resolves promptly, but joint symptoms can persist.

Chronic relapsing-remitting course with multisystem involvement

Viral testing and epidemiology support chikungunya. ANA and complement levels are not diagnostic criteria.

ANA is usually positive. Anti-dsDNA antibodies or low complement may support SLE in a compatible multisystem illness. Their absence alone cannot exclude it.

Viral infection with chikungunya virus

Autoimmune etiology without infectious cause